Status:
NOT_YET_RECRUITING
A Mass Balance Study of [14C]ABSK011
Lead Sponsor:
Abbisko Therapeutics Co, Ltd
Conditions:
Healthy Subjects
Eligibility:
MALE
18-45 years
Phase:
PHASE1
Brief Summary
This study is a single-site, open-label, single-cohort, single-dose study to assess the absorption, metabolism, and excretion profile of \[14C\] ABSK011 in healthy adult male subjects. The study plans...
Detailed Description
Participants will be screened no more than 14 days before the dose (D-14 through D-3) and admitted to the clinical trial unit 2 days before the dose (D-2). Participants will receive a single oral admi...
Eligibility Criteria
Inclusion
- Participants who fully understand the content, procedures and possible adverse reactions before the study, and voluntarily sign the informed consent form, and can complete the study in accordance with the requirements in the protocol;
- Healthy male participants aged 18 to 45 years (including 18 and 45 years) at screening;
- Weight ≥ 50 kg, body mass index (BMI) between 19 and 26 (including 19 and 26), BMI = weight (kg)/height (m) \^2;
- Participants must have regular defecation in the past three months;
- Male participants of childbearing potential must agree to use effective contraceptive methods during the study and within 6 months after administration of study drug . Male subjects must agree to not donate sperm during this period.
Exclusion
- Abnormal and clinically significant complete physical examination, vital signs, digital rectal examination, laboratory tests (hematology, blood biochemistry, urinalysis, coagulation function, stool routine + occult blood, thyroid function, etc.), 12-lead electrocardiogram, chest X-ray (anteroposterior position), abdominal B ultrasound (hepatobiliary, pancreas, spleen and kidney);
- Tested positive for any one of the following: serum hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg), hepatitis C virus (HCV) antibody, human immunodeficiency virus (HIV) antigen/antibody, treponema pallidum antibody (Syphilis) screening;
- The baseline of heart rate corrected QT, QTcF interval prolongs ≥450ms; family history of long QT syndrome (Note: QTc interval is corrected by Fridericia formula);
- Known or persistent mental disorders that may interfere with the subject's participation in the study, as judged by the investigator;
- Known history of allergy to any drug or food;
- Participants who have participated in drug trials within 3 months before dosing.
- Participants who have participated in this study or any other study related to ABSK011, and have previously exposed to ABSK011;
- Known history of drug abuse or tested positive in drug abuse screening;
- Participants with any other factors that may influence the participation in the study, which may affect the subject's compliance with the protocol, interfere with the interpretation of the study results, or expose the subject to risk, as judged by the investigator.
Key Trial Info
Start Date :
April 7 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 7 2026
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT06896760
Start Date
April 7 2025
End Date
April 7 2026
Last Update
March 26 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing GoBroad Hospital
Beijing, Beijing Municipality, China, 102206